about us

With the presence of hundreds of niche clinical service providers and dozens of large, global ones, the drug development market faces commoditisation due to the similarity in proposed services among them all.

The choice between clinical service partners is getting increasingly complex especially for large, global studies. Because of this, many biotech and pharmaceutical companies choose large CROs despite all their known drawbacks.  It is also easier for a sponsor to select a large firm as there is always one single point of contact.

Historically, only large CROs have offered complete drug development services on a global level whilst regionally located, niche CROs provided high quality, specialized services within their local region.  As each country has specific regulatory requirements and expectations to be met, local CROs are the better choice to meet these specific requirements.

  Large, global CROs provide:
     • A single point of contact
     • Global experience and capabilities

However, clinical trial sponsors are sometimes concerned with the work of large CROs because of:
     • High level of bureaucracy
     • Slow response time
     • High personnel fluctuation and employee turnover
     • Higher costs due to higher overheads

Clinical trial sponsors prefer to work with local, niche CROs because of their:
     • Expertise in specific regions & services
     • Experience and less employee turnover
     • Reliability
     • Results
     • High quality service

For a regional provider to grow and expand their geographic capabilities, they have to grow into a global organisation and lose the advantages that made them successful in the first place. We have developed a solution to this problem. The solution is the Clinterra Research Network.

Clinterra Research Network provides the depth of service and coverage of a global CRO plus the service level and value of a local CRO.